DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 2.27 EUR -0.22% Market Closed
Market Cap: 408.2m EUR

DBV Technologies SA
Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

DBV Technologies SA
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
DBV Technologies SA
PAR:DBV
Common Stock
$15.4m
CAGR 3-Years
13%
CAGR 5-Years
22%
CAGR 10-Years
23%
Valneva SE
PAR:VLA
Common Stock
€25.5m
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
9%
Nanobiotix SA
PAR:NANO
Common Stock
€1.4m
CAGR 3-Years
11%
CAGR 5-Years
16%
CAGR 10-Years
13%
Inventiva SA
PAR:IVA
Common Stock
€957k
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Common Stock
$5.9m
CAGR 3-Years
26%
CAGR 5-Years
16%
CAGR 10-Years
14%
Eurobio Scientific SA
PAR:ALERS
Common Stock
€3.3m
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
11%
No Stocks Found

DBV Technologies SA
Glance View

Market Cap
408.2m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
11.42 EUR
Undervaluation 80%
Intrinsic Value
Price

See Also

What is DBV Technologies SA's Common Stock?
Common Stock
15.4m USD

Based on the financial report for Jun 30, 2025, DBV Technologies SA's Common Stock amounts to 15.4m USD.

What is DBV Technologies SA's Common Stock growth rate?
Common Stock CAGR 10Y
23%

Over the last year, the Common Stock growth was 40%. The average annual Common Stock growth rates for DBV Technologies SA have been 13% over the past three years , 22% over the past five years , and 23% over the past ten years .

Back to Top